Author:
Fenton Caroline,Kang Connie
Publisher
Springer Science and Business Media LLC
Reference11 articles.
1. Cetin Gedik K, Arici ZS, Kul Cinar O, et al. Practical approach to diagnosis and management of IL-1-mediated autoinflammatory diseases (CAPS, TRAPS, MKD, and DIRA). Pediatr Drugs. 2024;26(2):113–26.
2. Li Y, Yu M, Lu M. Pathophysiology, clinical manifestations and current management of IL-1 mediated monogenic systemic autoinflammatory diseases, a literature review. Pediatr Rheumatol Online J. 2022;20(1):90.
3. Romano M, Arici ZS, Piskin D, et al. The 2021 EULAR/American College of Rheumatology points to consider for diagnosis, management and monitoring of the interleukin-1 mediated autoinflammatory diseases: cryopyrin-associated periodic syndromes, tumour necrosis factor receptor-associated periodic syndrome, mevalonate kinase deficiency, and deficiency of the interleukin-1 receptor antagonist. Ann Rheum Dis. 2022;81(7):907–21.
4. Delaleu J, Deshayes S, Rodrigues F, et al. Tumour necrosis factor receptor-1 associated periodic syndrome (TRAPS)-related AA amyloidosis: a national case series and systematic review. Rheumatology (Oxford). 2021;60(12):5775–84.
5. Yokota S, Imagawa T, Nishikomori R, et al. Long-term safety and efficacy of canakinumab in cryopyrin-associated periodic syndrome: results from an open-label, phase III pivotal study in Japanese patients. Clin Exp Rheumatol. 2017;35(Suppl. 108):S19-26.